

Haematologica  
HAEMATOL/2018/209015  
Version 3

Association of early disease progression and very poor survival in the  
GALLIUM study in follicular lymphoma: benefit of obinutuzumab in  
reducing the rate of early progression

John F. Seymour, Robert Marcus, Andrew Davies, Eve Gallop-Evans,  
Andrew Grigg, Andrew Haynes, Michael Herold, Thomas Illmer,  
Herman Nilsson-Ehle, Martin Sökler, Ulrich Dünzinger, Tina Nielsen,  
Aino Launonen, and Wolfgang Hiddemann

Disclosures: JFS has received honoraria and consulting or advisory fees from AbbVie, Celgene, Genentech, Gilead, Janssen, Roche, and Takeda; received research funding from AbbVie and Janssen; and received travel support from Celgene and Roche. AG has received consulting or advisory fees and travel support from Roche. RM has received honoraria, consulting or advisory fees, and speakers' bureau from Roche. AD has received honoraria from Celgene, CTI, Mundipharma, Roche, Gilead, Takeda, Janssen, and Pfizer; consulting or advisory fees from Karyopharma, KiTe, and Acerta; and research funding from Celgene, Roche, Gilead, Takeda, GSK, Bayer, Janssen, Pfizer, and Acerta. EG has received consulting or advisory fees from Roche. MH has received consulting or advisory fees, speakers' bureau, and research funding from Roche. TI has received research funding from Roche. HN has received honoraria from Pfizer, Mundipharma, and Roche; and consulting or advisory fees from Mundipharma, Roche, and Gilead. WH has received honoraria, consulting or advisory fees, and research funding from Roche, Janssen, and Celgene. AH and MS have no relationships to disclose. TN, UD, and AL are employees of Roche.

Contributions: Conception and Design: JFS Provision of Study Materials or Patients: JFS  
Collection and Assembly of Data: Data Analysis and Interpretation: JFS Manuscript  
Writing: All Authors Final Approval of Manuscript: All Authors Accountable for all Aspects of  
the Work: All Authors